Join Growin Stock Community!

Anixa biosciences, inc.ANIX.US Overview

US StockHealthcare
(No presentation for ANIX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ANIX AI Insights

ANIX Overall Performance

ANIX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ANIX Recent Performance

-1.34%

Anixa biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ANIX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ANIX Key Information

ANIX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ANIX Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Price of ANIX

ANIX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
481.54
PB Ratio
6.69
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.33
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
481.54
PB Ratio
6.69
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ANIX's latest earnings report released?

    The most recent financial report for Anixa biosciences, inc. (ANIX) covers the period of 2025Q4 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ANIX's short-term business performance and financial health. For the latest updates on ANIX's earnings releases, visit this page regularly.

  • How much debt does ANIX have?

    As of the end of the reporting period, Anixa biosciences, inc. (ANIX) had total debt of 204K, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ANIX have?

    At the end of the period, Anixa biosciences, inc. (ANIX) held Total Cash and Cash Equivalents of 1.24M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of ANIX?

    Anixa biosciences, inc. (ANIX)'s Free Cash Flow (FCF) for the period is -1.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 35.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ANIX?

    The latest valuation data shows Anixa biosciences, inc. (ANIX) has a Price-To-Earnings (PE) ratio of -9.65 and a Price/Earnings-To-Growth (PEG) ratio of -0.71. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

ANIX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1